• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ: SLN )

6.880 +0.540 (+8.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
November 18, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 13, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
April 29, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
February 28, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
February 23, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 05, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
December 01, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 14, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 08, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
November 01, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 26, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in September Investor Conferences
September 06, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Second Quarter 2023 Results
August 16, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
July 11, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap